X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (287) 287
Newspaper Article (92) 92
Patent (87) 87
Book Chapter (21) 21
Book / eBook (10) 10
Magazine Article (9) 9
Book Review (8) 8
Web Resource (2) 2
Dissertation (1) 1
Report (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (140) 140
index medicus (93) 93
melanoma (85) 85
female (84) 84
chemistry (82) 82
metallurgy (81) 81
organic chemistry (71) 71
male (70) 70
human necessities (68) 68
hygiene (68) 68
medical or veterinary science (68) 68
peptides (68) 68
oncology (66) 66
preparations for medical, dental, or toilet purposes (66) 66
adult (63) 63
middle aged (60) 60
physics (55) 55
testing (53) 53
measuring (52) 52
investigating or analysing materials by determining theirchemical or physical properties (51) 51
aged (47) 47
melanoma - pathology (44) 44
immunotherapy (40) 40
cancer (37) 37
specific therapeutic activity of chemical compounds ormedicinal preparations (37) 37
metastasis (35) 35
microbiology (35) 35
immunology (34) 34
beer (33) 33
biochemistry (33) 33
enzymology (33) 33
mutation or genetic engineering (33) 33
spirits (33) 33
vinegar (33) 33
wine (33) 33
survival (32) 32
metastatic melanoma (31) 31
melanoma - drug therapy (30) 30
metastases (27) 27
skin neoplasms - pathology (27) 27
treatment outcome (27) 27
aged, 80 and over (24) 24
patients (24) 24
melanoma - immunology (23) 23
adolescent (22) 22
skin neoplasms - drug therapy (22) 22
culture media (21) 21
ipilimumab (21) 21
malignant-melanoma (21) 21
melanoma - genetics (21) 21
compositions thereof (20) 20
melanoma - therapy (20) 20
microorganisms or enzymes (20) 20
neoplasm staging (20) 20
propagating, preserving or maintaining microorganisms (20) 20
animals (19) 19
mutation (19) 19
tumor-infiltrating lymphocytes (19) 19
care and treatment (18) 18
disease-free survival (18) 18
melanoma - mortality (18) 18
therapy (18) 18
chemotherapy (17) 17
lymphocytes, tumor-infiltrating - immunology (17) 17
prognosis (17) 17
analysis (16) 16
expression (15) 15
health aspects (15) 15
lymphocytes (15) 15
risk factors (15) 15
skin neoplasms - mortality (15) 15
surgery (15) 15
cell line, tumor (14) 14
compositions or test papers therefor (14) 14
condition-responsive control in microbiological orenzymological processes (14) 14
cutaneous melanoma (14) 14
follow-up studies (14) 14
measuring or testing processes involving enzymes, nucleicacids or microorganisms (14) 14
melanoma - metabolism (14) 14
processes of preparing such compositions (14) 14
research (14) 14
skin cancer (14) 14
skin neoplasms - genetics (14) 14
young adult (14) 14
clinical trials (13) 13
management (13) 13
melanoma - secondary (13) 13
retrospective studies (13) 13
tumors (13) 13
adoptive cell therapy (12) 12
biometrics (12) 12
biostatistics (12) 12
cancer regression (12) 12
health care industry (12) 12
responses (12) 12
time factors (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
disease progression (11) 11
health information (11) 11
health sciences (11) 11
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Law (Bora Laskin) - Stacks (2) 2
Online Resources - Online (2) 2
Robarts - Stacks (2) 2
Business (Joseph L Rotman) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (502) 502
French (26) 26
German (14) 14
Spanish (12) 12
Chinese (5) 5
Portuguese (4) 4
Hebrew (3) 3
Korean (3) 3
Polish (3) 3
Croatian (2) 2
Lithuanian (2) 2
Danish (1) 1
Greek (1) 1
Hungarian (1) 1
Romanian (1) 1
Russian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of clinical investigation, ISSN 0021-9738, 2013, Volume 123, Issue 6, pp. 2703 - 2718
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 26, pp. 2521 - 2532
Journal Article
The lancet oncology, ISSN 1470-2045, 2019, Volume 20, Issue 9, pp. 1239 - 1251
SummaryBackgroundPembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a... 
Hematology, Oncology, and Palliative Medicine | SURVIVAL | ONCOLOGY | NIVOLUMAB | Ipilimumab | Analysis
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 5, pp. 616 - 622
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 7, pp. 626 - 636
In long-term follow-up of more than 500 patients with melanoma containing a BRAF V600E or V600K mutation, a combination of dabrafenib plus trametinib was... 
SURVIVAL | DOUBLE-BLIND | MEDICINE, GENERAL & INTERNAL | POOLED ANALYSIS | BRAF | IPILIMUMAB | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | MAP Kinase Kinase Kinases - antagonists & inhibitors | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Survival Rate | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Progression-Free Survival | Adolescent | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Drug therapy | Patient outcomes | Risk factors | Skin cancer | Dehydrogenases | MEK inhibitors | Melanoma | Clinical trials | Metastasis | Multivariate analysis | Survival | Patients | L-Lactate dehydrogenase | Metastases | Medical prognosis | Response rates | Biomarkers | Lactic acid
Journal Article